Markets:

Overview

News

Currencies

International

Treasuries

Mind Cure Health Inc (OP:MCURF)

N/A UNCHANGED

Last Price Updated: 2:36 PM EDT, Sep 11, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Mind Cure Health Inc

Cannabis Movers & Shakers: TrueGreen, PSYC, BioSteel Sports Nutrition, Perfect Union, YourWay Cannabis Brands ↗

April 12, 2022

Via Benzinga

Are Psychedelics Stocks In Trouble Or Is The Market Reaching Maturity? ↗

April 04, 2022

Long gone is the heyday of investor enthusiasm and easy access to capital that marked the launch of the psychedelics industry into the public markets. In recent months, psychedelics stocks entered into...

Via Benzinga

Psyched: MindCure Shuts Down Operations, Novamind And MindMed Partner For Study ↗

March 22, 2022

The psychedelics space was shaken up on the news thatMindCure Health (OTC: MCURF) was shutting down operations.

Via Benzinga

Mind Cure Health Is Shutting Down All Operations, Citing Lack Of Funds To Move Forward ↗

March 16, 2022

Mind Cure Health Inc. (CSE:MCUR) (OTCQX:

Via Benzinga

Benzinga Expands Footprint into the Psychedelic Industry with the Launch of the Benzinga Psychedelic Advisory Council ↗

March 09, 2022

DETROIT, March 4, 2022 /PRNewswire/ -- The Benzinga Psychedelics Advisory Council is a collective of the leading minds and voices in the ...

Via Benzinga

Psychedelics As A Potential Form Of Treatment For Traumatic Brain Injuries ↗

April 20, 2021

In recent years, there has been a re-emergence in the study of psychedelic drug...

Via Benzinga

Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday ↗

December 14, 2021

Photo by Chris Montgomery on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness ↗

December 08, 2021

Photo by Michael Longmire on...

Via Benzinga

EXCLUSIVE: Benzinga Interviews Mind Cure CEO Kelsey Ramsden with Updates on Latest Press Release ↗

November 09, 2021

Image by: iStock The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored conte...

Via Benzinga

Compass Pathways 2.0: A New Rally In Psychedelic Stocks? ↗

November 04, 2021

Compass Pathways' IPO sparked a sector-wide rally in 2020. Now CMPS is on the move again. Is history about to repeat?

Via Talk Markets

Topics Initial Public Offering

Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation ↗

November 01, 2021

The Week In Psychedelics:

Via Benzinga

Topics Intellectual Property

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations ↗

October 12, 2021

Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets.

Via Talk Markets

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction ↗

October 04, 2021

The Week In Psychedelics:

Via Benzinga

Can MDMA (Or Ecstasy) Improve Sexual Desire in Women? MindCure Launches Research Program To Find Out ↗

September 27, 2021

Mind Cure Health Inc. (CSE:MCUR) (OTCQB:

Via Benzinga

Is Ketamine A Psychedelic? Depends On Who You Ask ↗

September 22, 2021

Ketamine, an FDA-approved anesthetic drug, has recently become the star of the psychedelic medicine movement. As p...

Via Benzinga

Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗

September 09, 2021

By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...

Via Benzinga

Psychedelic Drug Industry Report Card For 2021 ↗

September 01, 2021

In assessing the psychedelic drug industry, a primary focus for investors is drug development.

Via Talk Markets

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold ↗

August 30, 2021

Contents

Via Benzinga

Which Psychedelic Drug Has The Most Commercial Potential? ↗

August 10, 2021

As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis.

Via Talk Markets

How To Invest In "Magic Mushrooms" (Psychedelics) ↗

July 09, 2021

A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.

Via Talk Markets

Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies ↗

July 02, 2021

Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o...

Via Benzinga

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More ↗

June 30, 2021

Institutional analysts are taking a liking to the industry ...

Via Benzinga

Professional Sports Turn To Psychedelics ↗

May 15, 2021

Psychedelic drug R&D is rapidly expanding into many of the largest medical treatment markets.

Via Talk Markets

Why Smaller Psychedelics Companies Should Start Catching Up To The Sector Leaders ↗

May 05, 2021

Concentration of ownership in psychedelic drug stocks has reached a new extreme. We explain how and why we don't see this trend as being sustainable.

Via Talk Markets

The Next Psychedelic Stock To Uplist On The Nasdaq? ↗

May 04, 2021

As MindMed Inc makes its long-awaited move to the Nasdaq, the obvious question is: who's next?

Via Talk Markets

Second-Chance Buying Opportunity With Psychedelic Stock Warrants ↗

April 27, 2021

Psychedelic stock warrants delivered epic returns for investors in the big rally in these stocks in 2020. After the pullback in 2021, some of these warrants are again looking attractive.

Via Talk Markets

Déjà Vu: 2021 Slump In Psychedelic Stocks Mirrors 2020 ↗

April 21, 2021

Charts for most psychedelic drug stocks look terrible in recent weeks. The same was true in the summer of 2020 -- immediately before these stocks exploded higher. Deja vu?

Via Talk Markets

Cannabis Movers & Shakers: TILT, BRNT, ECGI, Alcanna, WeedMD, Mind Cure, Flowr Corporation, VIVO, Cannabiz, Team Hytiva ↗

April 16, 2021

TILT Holdings Announces Two New Additions To Its Leadership Team TILT Holdings Inc. (CSE:

Via Benzinga

Topics Cannabis

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Mind Cure Health Inc (OP:MCURF)

Headline News about Mind Cure Health Inc

Starting at $3.75/week.

Subscribe Today